We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
- Authors
Dum, David; Kromm, Daniela; Lennartz, Maximilian; De Wispelaere, Nóemi; Büscheck, Franziska; Luebke, Andreas M.; Burandt, Eike; Menz, Anne; Kluth, Martina; Hube-Magg, Claudia; Hinsch, Andrea; Höflmayer, Doris; Weidemann, Sören; Fraune, Christoph; öller, Katharina M.; Lebok, Patrick; Sauter, Guido; Simon, Ronald; Uhlig, Ria; Wilczak, Waldemar
- Abstract
Context.--Special AT-rich sequence--binding protein 2 (SATB2) induces local chromatin loops to facilitate transcription. SATB2 immunostaining is commonly used as a marker for colorectal adenocarcinoma and osteosarcoma. Objective.--To extend our knowledge on the diagnostic value of SATB2 analysis in a comprehensive set of human tumors. Design.--Tissue microarrays with 15 012 samples from 120 tumor types and 608 samples of 76 different normal tissues were analyzed. Results.--SATB2 positivity was found in 89 of 120 different tumor types (74%), including 59 of 120 (49%) with at least 1 moderately positive tumor and 38 of 120 tumor types (32%) with at least 1 strongly positive tumor. Expression was frequent in adenomas (44/42--47/44; 94%-- 96% positive), adenocarcinomas (1747 of 2023; 86%), and various subtypes of neuroendocrine neoplasms (3/7-- 12/12; 43%--100%) of the colorectum and appendix, Merkel cell carcinoma (25 of 34, 74%), osteosarcomas (15 of 25; 60%), and papillary renal cell carcinoma (RCC) (121 of 235; 52%). Associations to clinicopathologic tumor features were assessed in colorectal and kidney cancers. In colorectal cancer, weak SATB2 expression was linked to high pT (P < .001), nodal metastasis (P < .001), right-sided tumor location (P < .001), microsatellite instability (P < .001), and BRAF mutations (P = .02). In papillary RCC, low SATB2 expression was associated with high pT (P = .02), distant metastasis (P = .04), and reduced tumor-specific survival (P = .04). In clear cell RCC, low SATB2 expression was linked to high pT (P < .001), high Union for International Cancer Control stage (P < .001), high Thoenes grade (P = .02), and reduced recurrence-free survival (P = .02). Conclusions.--Strong SATB2 expression argues for a colorectal origin within adenocarcinomas and neuroendocrine neoplasms. Weak SATB2 expression reflects progression and poor prognosis in colorectal and kidney cancer.
- Subjects
RISK of metastasis; TUMOR genetics; TUMOR diagnosis; PROTEINS; ADENOCARCINOMA; RENAL cell carcinoma; GENETIC mutation; OSTEOSARCOMA; ONCOGENES; ADENOMA; CANCER relapse; GENE expression; COLORECTAL cancer; GENETIC markers; NEUROENDOCRINE tumors; SURVIVAL analysis (Biometry); TRANSCRIPTION factors; MERKEL cell carcinoma; PROGRESSION-free survival; DISEASE risk factors
- Publication
Archives of Pathology & Laboratory Medicine, 2023, Vol 147, Issue 4, p451
- ISSN
0003-9985
- Publication type
Article
- DOI
10.5858/arpa.2021-0317-OA